| [1] |
Gauthier S, Rosa-Neto P, Morais JA, et al. World Alzheimer report 2021-Journey through the diagnosis of dementia[EB/OL]. London: Alzheimer’s Disease International, 2021.
URL
|
| [2] |
Wu YT, Ali GC, Guerchet M, et al. Prevalence of dementia in mainland China, Hong Kong and Taiwan: an updated systematic review and meta-analysis[J]. Int J Epidemiol, 2018, 47(3): 709-719.
|
| [3] |
Jia J, Wei C, Chen S, et al. The cost of Alzheimer’s disease in China and re-estimation of costs worldwide[J]. Alzheimers Dement, 2018, 14(4): 483-491.
|
| [4] |
Vaz M, Silvestre S. Alzheimer’s disease: recent treatment strategies[J]. Eur J Pharmacol, 2020, 887: 173554.
|
| [5] |
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Center for biologics evaluation guidance for industry Alzheimer’s disease: developing drugs for the treatment of early stage disease[EB/OL]. 2013.
URL
|
| [6] |
European Medicines Agency, Committee For Medicinal Products For Human Use (CHMP). Guideline on medicinal products for the treatment of Alzheimer’s Disease and other dementias[EB/OL]. 2008.
URL
|
| [7] |
European Medicines Agency, Committee For Medicinal Products For Human Use (CHMP). Clinical investigation of medicines for the treatment of Alzheimer’s disease[EB/OL]. 2018.
URL
|
| [8] |
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), et al. Early Alzheimer’s disease: developing drugs for treatment, guidance for industry[EB/OL]. 2018.
URL
|
| [9] |
关亮.治疗阿尔茨海默病药物临床试验技术指导原则[J].中国现代医生, 2007, 45(20): 72-75.
|
| [10] |
阿尔茨海默病创新药物临床试验中国专家小组.阿尔茨海默病创新药物临床试验中国专家共识[J].中华老年病研究电子杂志, 2016, 3(1): 1-11.
|
| [11] |
Mangialasche F, Solomon A, Winblad B, et al. Alzheimer’s disease: clinical trials and drug development[J]. Lancet Neurol, 2010, 9(7): 702-716.
|
| [12] |
Atri A, Frölich L, Ballard C, et al. Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: three randomized clinical trials[J]. JAMA, 2018, 319(2): 130-142.
|
| [13] |
Fujino T, Yamada T, Asada T, et al. Efficacy and blood plasmalogen changes by oral administration of plasmalogen in patients with mild Alzheimer’s disease and mild cognitive impairment: a multicenter, randomized, double-blind, placebo-controlled trial[J]. EBioMedicine, 2017, 17: 199-205.
|
| [14] |
Decourt B, Drumm-Gurnee D, Wilson J, et al. Poor safety and tolerability hamper reaching a potentially therapeutic dose in the use of thalidomide for Alzheimer’s disease: results from a double-blind, placebo-controlled trial[J]. Curr Alzheimer Res, 2017, 14(4): 403-411.
|
| [15] |
Wang T, Kuang W, Chen W, et al. A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia[J]. Alzheimers ResTher, 2020, 12(1): 110.
|
| [16] |
Hager K, Baseman AS, Nye JS, et al. Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study[J]. Alzheimers Res Ther, 2016, 8(1): 47.
|
| [17] |
Cummings JL, Cohen S, van Dyck CH, et al. ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease[J]. Neurology, 2018, 90(21): e1889-e1897.
|
| [18] |
Ostrowitzki S, Lasser RA, Dorflinger E, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease[J]. Alzheimers Res Ther, 2017, 9(1): 95.
|
| [19] |
Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria[J]. Lancet Neurol, 2007, 6(8): 734-746.
|
| [20] |
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease[J]. Alzheimers Dement, 2011, 7(3): 263-269.
|
| [21] |
Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria[J]. Lancet Neurol, 2014, 13(6): 614-629.
|
| [22] |
Nakamura Y, Kitamura S, Homma A, et al. Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer’s disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan[J]. Expert Opin Pharmacother, 2014, 15(7): 913-925.
|
| [23] |
Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease[J]. N Engl J Med, 2018, 378(4): 321-330.
|
| [24] |
Hannestad J, Duclos T, Chao W, et al. Safety and tolerability of GRF6019 infusions in severe Alzheimer’s disease: a phase II double-blind placebo-controlled trial[J]. J Alzheimers Dis, 2021, 81(4): 1649-1662.
|
| [25] |
Rafii MS, Aisen PS. Alzheimer’s disease clinical trials: moving toward successful prevention[J]. CNS Drugs, 2019, 33(2): 99-106.
|
| [26] |
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease[J]. Alzheimers Dement, 2018, 14(4): 535-562.
|
| [27] |
Morris JC. The clinical dementia rating (CDR): current version and scoring rules[J]. Neurology, 1993, 43(11): 2412-2414.
|
| [28] |
Reisberg B, Ferris SH, de Leon MJ, et al. Global Deterioration Scale (GDS)[J]. Psychopharmacol Bull, 1988, 24(4): 661-663.
|
| [29] |
Rikkert MG, Tona KD, Janssen L, et al. Validity, reliability, and feasibility of clinical staging scales in dementia: a systematic review[J]. Am J Alzheimers Dis Other Demen, 2011, 26(5): 357-365.
|
| [30] |
Ferrero J, Williams L, Stella H, et al. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer’s disease[J]. Alzheimers Dement (N Y), 2016, 2(3): 169-176.
|
| [31] |
Gault LM, Lenz RA, Ritchie CW, et al. ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension[J]. Alzheimers Res Ther, 2016, 8(1): 44.
|
| [32] |
Lozupone M, Solfrizzi V, D’Urso F, et al. Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs[J]. Expert Opin Emerg Drugs, 2020, 25(3): 319-335.
|
| [33] |
Coric V, Salloway S, van Dyck CH, et al. Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial[J]. JAMA Neurol, 2015, 72(11): 1324-1333.
|
| [34] |
Craft S, Raman R, Chow TW, et al. Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial[J]. JAMA Neurol, 2020, 77(9): 1099-1109.
|
| [35] |
Lowe SL, Duggan Evans C, Shcherbinin S, et al. Donanemab (LY3002813) phase 1b study in Alzheimer’s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging[J]. J Prev Alzheimers Dis, 2021, 8(4): 414-424.
|
| [36] |
Maher-Edwards G, Watson C, Ascher J, et al. Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer’s disease[J]. Alzheimers Dement (N Y), 2015, 1(1): 23-36.
|
| [37] |
Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer’s disease[J]. J Alzheimers Dis, 2015, 44(2): 705-720.
|
| [38] |
Jia J, Ji Y, Feng T, et al. Sixteen-week interventional study to evaluate the clinical effects and safety of rivastigmine capsules in Chinese patients with Alzheimer’s disease[J]. J Alzheimers Dis, 2019, 72(4): 1313-1322.
|
| [39] |
Maier F, Spottke A, Bach JP, et al. Bupropion for the treatment of apathy in Alzheimer disease: a randomized clinical trial[J]. JAMA Netw Open, 2020, 3(5): e206027.
|
| [40] |
Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody[J]. Alzheimers Res Ther, 2021, 13(1): 80.
|
| [41] |
Wang HY, Pei Z, Lee KC, et al. PTI-125 reduces biomarkers of Alzheimer’s disease in patients[J]. J Prev Alzheimers Dis, 2020, 7(4): 256-264.
|
| [42] |
Scheltens P, Hallikainen M, Grimmer T, et al. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study[J]. Alzheimers Res Ther, 2018, 10(1): 107.
|
| [43] |
Vijverberg EGB, Axelsen TM, Bihlet AR, et al. Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD[J]. Alzheimers Res Ther, 2021, 13(1): 142.
|
| [44] |
Farlow MR, Thompson RE, Wei LJ, et al. A randomized, double-blind, placebo-controlled, phase II study assessing safety, tolerability, and efficacy of bryostatin in the treatment of moderately severe to severe Alzheimer’s disease[J]. J Alzheimers Dis, 2019, 67(2): 555-570.
|
| [45] |
Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline[J]. JAMA Neurol, 2014, 71(8): 961-970.
|
| [46] |
Xiao S, Chan P, Wang T, et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia[J]. Alzheimers Res Ther, 2021, 13(1): 62.
|
| [47] |
Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients[J]. Alzheimers Dement, 2016, 12(2): 110-120.
|
| [48] |
Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial[J]. Lancet, 2016, 388(10062): 2873-2884.
|
| [49] |
Sabbagh MN, Hendrix S, Harrison JE. FDA position statement "Early Alzheimer’s disease: developing drugs for treatment, guidance for industry" [J]. Alzheimers Dement (N Y), 2019, 5: 13-19.
|
| [50] |
Salloway S, Honigberg LA, Cho W, et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)[J]. Alzheimers Res Ther, 2018, 10(1): 96.
|
| [51] |
Farlow MR, Andreasen N, Riviere ME, et al. Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease[J]. Alzheimers Res Ther, 2015, 7(1): 23.
|
| [52] |
Howard R, Zubko O, Bradley R, et al. Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease: a randomized clinical trial[J]. JAMA Neurol, 2020, 77(2): 164-174.
|
| [53] |
Padala PR, Boozer EM, Lensing SY, et al. Neuromodulation for apathy in Alzheimer’s disease: a double-blind, randomized, sham-controlled pilot study[J]. J Alzheimers Dis, 2020, 77(4): 1483-1493.
|
| [54] |
Turner RS, Thomas RG, Craft S, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease[J]. Neurology, 2015, 85(16): 1383-1391.
|
| [55] |
Gejl M, Gjedde A, Egefjord L, et al. In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial[J]. Front Aging Neurosci, 2016, 8: 108.
|
| [56] |
Zhao L, Zhao Q, Zhou Y, et al. Atorvastatin may correct dyslipidemia in adult patients at risk for Alzheimer’s disease through an anti-inflammatory pathway[J]. CNS Neurol Disord Drug Targets, 2016, 15(1): 80-85.
|
| [57] |
Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer’s disease[J]. N Engl J Med, 2021, 384(18): 1691-1704.
|
| [58] |
Yoshida K, Moein A, Bittner T, et al. Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease[J]. Alzheimers Res Ther, 2020, 12(1): 16.
|
| [59] |
Malpas CB, Vivash L, Genc S, et al. A phase IIa randomized control trial of VEL015 (sodium selenate) in mild-moderate Alzheimer’s disease[J]. J Alzheimers Dis, 2016, 54(1): 223-232.
|
| [60] |
Henderson ST, Morimoto BH, Cummings JL, et al. A placebo-controlled, parallel-group, randomized clinical trial of AC-1204 in mild-to-moderate Alzheimer’s disease[J]. J Alzheimers Dis, 2020, 75(2): 547-557.
|
| [61] |
Novak P, Schmidt R, Kontsekova E, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial[J]. Lancet Neurol, 2017, 16(2): 123-134.
|
| [62] |
Prins ND, Harrison JE, Chu HM, et al. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease[J]. Alzheimers Res Ther, 2021, 13(1): 106.
|
| [63] |
Heritier SR, Gebski VJ, Keech AC. Inclusion of patients in clinical trial analysis: the intention-to-treat principle[J]. Med J Aust, 2003, 179(8): 438-440.
|
| [64] |
Moreno-Betancur M, Chavance M. Sensitivity analysis of incomplete longitudinal data departing from the missing at random assumption: methodology and application in a clinical trial with drop-outs[J]. Stat Methods Med Res, 2016, 25(4): 1471-1489.
|
| [65] |
Malek-Ahmadi M, Chen K, Perez SE, et al. Cognitive composite score association with Alzheimer’s disease plaque and tangle pathology[J]. Alzheimers Res Ther, 2018, 10(1): 90.
|
| [66] |
Donohue MC, Aisen PS. Mixed model of repeated measures versus slope models in Alzheimer’s disease clinical trials[J]. J Nutr Health Aging, 2012, 16(4): 360-364.
|